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Objective:Diabetes mellitus has been associated with an increased risk of adverse out-
comes after coronary artery bypass grafting. Hemoglobin A1c is a reliable measure of
long-term glucose control. It is unknown whether adequacy of diabetic control, mea-
sured by hemoglobin A1c, is a predictor of adverse outcomes after coronary artery
bypass grafting.
Methods:Of 3555 consecutive patients who underwent primary, elective coronary ar-
tery bypass grafting at a single academic center from April 1, 2002, to June 30, 2006,
3089 (86.9%) had preoperative hemoglobin A1c levels obtained and entered prospec-
tively into a computerized database. All patients were treated with a perioperative in-
travenous insulin protocol. A multivariable logistic regression model was used to
determine whether hemoglobin A1c, as a continuous variable, was associated with
in-hospital mortality, renal failure, cerebrovascular accident, myocardial infarction,
and deep sternal wound infection after coronary artery bypass grafting. Receiver op-
erating characteristic curve analysis identified the hemoglobin A1c value that maxi-
mally discriminated outcome dichotomies.
Results: In-hospital mortality for all patients was 1.0% (31/3089). An elevated hemo-
globin A1c level predicted in-hospital mortality after coronary artery bypass grafting
(odds ratio 1.40 per unit increase, P 5 .019). Receiver operating characteristic curve
analysis revealed that hemoglobin A1c greater than 8.6% was associated with a 4-fold
increase in mortality. For each unit increase in hemoglobin A1c, there was a signifi-
cantly increased risk of myocardial infarction and deep sternal wound infection. By
using receiver operating characteristic value thresholds, renal failure (threshold 6.7,
odds ratio 2.1), cerebrovascular accident (threshold 7.6, odds ratio 2.24), and deep
sternal wound infection (threshold 7.8, odds ratio 5.29) occurred more commonly
in patients with elevated hemoglobin A1c.
Conclusion: Elevated hemoglobin A1c level was strongly associated with adverse
events after coronary artery bypass grafting. Preoperative hemoglobin A1c testing
may allow for more accurate risk stratification in patients undergoing coronary artery
bypass grafting.
D
iabetes mellitus has long been recognized as an independent risk factor for
the development of coronary artery disease.1 Although the literature is replete
with studies in patients undergoing coronary artery bypass grafting (CABG)
comparing outcomes in diabetic patients versus nondiabetic patients,2–9 the impact of
preoperative glucose control on outcomes has not been extensively studied.10 Previ-
ous studies have used methods of glucose control (ie, diet vs oral hypoglycemics vs
insulin) as a means to stratify outcomes.2,3,7 Moreover, because a spot preoperative
glucose level is highly variable, it is unclear whether these treatment strategies
were effective in achieving acceptable diabetes control before CABG. This is in con-
trast with perioperative glucose control, which has a significantly favorable impact on
postoperative outcomes.10–15
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CDAbbreviations and Acronyms
AUROC 5 area under the receiver operating characteristic
CABG 5 coronary artery bypass grafting
CPB 5 cardiopulmonary bypass
CVA 5 cerebrovascular accident
DSWI 5 deep sternal wound infection
HbA1C 5 hemoglobin A1c
LOS 5 length of stay
MI 5 myocardial infarction
OR 5 odds ratio
The American Diabetes Association has recommended
the use of the blood hemoglobin A1c (HbA1c) level as
a method of assessing long-term glycemic control in diabetic
patients.16 HbA1c, also known as glycosylated hemoglobin,
indicates a patient’s blood glucose control during the previ-
ous 3 to 4 months. HbA1c is formed when glucose in the
blood binds irreversibly to hemoglobin to form a stable gly-
cated hemoglobin complex. Because the normal life span of
red blood cells is 90 to 120 days, HbA1c will only be elimi-
nated when red cells are replaced. Because red cell turnover is
continuous and HbA1c is not affected by short-term glycemic
lability, HbA1c allows better assessment of glucose control
during a 3- to 4-month time period. The American Diabetes
Association currently recommends that patients with diabetes
achieve HbA1c levels less than 7%, which is associated with
a lower risk of diabetes-associated complications.17,18
We previously reported the detrimental effects of diabetes
on the outcomes after CABG; however, that study did not
take into account the influence of preoperative blood glucose
control.2 The current study was performed to more specifi-
cally evaluate the role of preoperative blood glucose control
(using the surrogate HbA1c laboratory value) on in-hospital
outcomes after primary, elective, isolated CABG. Therefore,
the purpose of this study was to 1) assess whether elevated
HbA1c can be used as a risk factor for morbidity and mortal-
ity after CABG; 2) determine whether patients with well-con-
trolled diabetes preoperatively (HbA1c , 7%) had better
outcomes compared with patients with poorly controlled di-
abetes preoperatively (HbA1c $ 7%); 3) determine whether
patients with well-controlled diabetes (HbA1c , 7%) have
outcomes comparable to those without a history of diabetes;
and 4) validate the American Diabetes Association recom-
mended HbA1c thresholds and provide thresholds for previ-
ously unstudied adverse outcomes after CABG.
Materials and Methods
In compliance with Health Insurance Portability and Accountability
Act of 1996 regulations and the Declaration of Helsinki, and after
institutional review board approval granted by Emory University,
the Society of Thoracic Surgeons Adult Cardiac Database was que-632 The Journal of Thoracic and Cardiovascular Surgery c Sepried for all patients who underwent isolated, elective, primary
CABG at Emory University Hospital, Emory Crawford Long Hos-
pital, and Wellstar Kennestone Hospital from April 1, 2002, to June
30, 2006. This period of study coincides with the entire period dur-
ing which preoperative HbA1c levels were routinely collected in pa-
tients scheduled for cardiac surgery. All data for consecutive
patients were prospectively entered into a computerized cardiac sur-
gical database, using the data fields and definitions of the Society of
Thoracic Surgeons National Adult Cardiac Database. Data were
managed by local database staff and warehoused in locked, secure
facilities, protected by computer passwords and firewalls.
Cardiopulmonary bypass (CPB) was used according to the dis-
cretion of the attending surgeon. Conventional CABG with CPB
was performed with standard techniques, using roller head pumps,
membrane oxygenators, cardiotomy suction, arterial filters, cold an-
tegrade or retrograde blood cardioplegia, and moderate systemic hy-
pothermia (32C–34C). Off-pump CABG was performed with one
of several commercially available cardiac positioning and coronary
artery stabilizing devices. Patients who were converted intraopera-
tively from off-pump CABG to conventional CABG were entered
into the database and analyzed according to the operation they ulti-
mately received.
All patients were treated with a uniform perioperative intrave-
nous insulin protocol. In the operating room, an insulin infusion
was premixed with 125 units of insulin in 250 mL 0.9% normal sa-
line. Routinemeasurement of blood glucosewas obtained from serial
arterial blood gases measured every 30 minutes. In the intensive care
unit, glucose levels were obtained from arterial blood gas samples or
finger stick samples every 2 hours. Once patients were transferred to
the floor, blood glucose valueswere obtained every 4 to 6 hours. Glu-
cose levels were obtained via arterial samples in the operating room
and the intensive care unit and via finger stick blood samples on the
floor. The insulin infusion was initiated for blood glucose more than
120 mg/dL and adjusted to target intraoperative blood glucose be-
tween 80 and 110 mg/dL according to the discretion of the attending
cardiac anesthesiologist. In the intensive care unit, patients received
a continuous insulin infusion thatwas adjusted tomaintain blood glu-
cose between 80 and 110 mg/dL according to a sliding scale (blood
glucose – 603 0.045 units of insulin per hour). On transfer out of
the intensive care unit, most patients are monitored with blood glu-
cose monitoring every 4 to 6 hours (goal blood glucose , 150
mg/dL) and maintained according to the sliding scale with subcuta-
neous insulin in addition to their preoperative subcutaneous regi-
mens. If necessary to achieve glucose control, continuous insulin
infusion was continued after transfer out of the intensive care unit.
Patients with newly diagnosed or poorly controlled diabetes also
received endocrinology consultation for better control in the postop-
erative period. To adjust for the effect of perioperative glucose, 2
different mean glucose values were computed and modeled: the
mean glucose value for the day of surgery and the mean glucose
value for postoperative days 1 to 3. The blood glucose level was
used as a continuous variable in the multivariable analysis.
Analytically, this study aimed to determinewhether HbA1cwas an
independent risk factor of adverse outcomes. To this end, a total of 22
covariates were collected to use as risk adjustors to ensure that the ef-
fect ofHbA1cwasnot confounded by their influence. These covariates
are listed in Table 1 by HbA1c groupings (,7% and $7%). The
HbA1c classifications were chosen according to recommendationstember 2008
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HbA1c of less than 7%.17,18 Race was modeled as a binary variable
(caucasian or non-caucasian), as was New York Heart Association
classification (class 4 or non-class 4), Canadian Cardiovascular Soci-
ety classification (class 4 or non-class 4), and chronic lung disease
(presence or absence). The outcomes collected for consideration
were in-hospital mortality, renal failure, myocardial infarction (MI),
cerebrovascular accident (CVA), deep sternal wound infection
(DSWI), presence of any infection (superficial or DSWI, pneumonia
or septicemia), atrial fibrillation, and postoperative length of stay
(LOS).
Missing data were present in race (n5 83), New York Heart As-
sociation classification (n 5 35), and Canadian Cardiovascular So-
ciety classification (n 5 38). To prevent patients with missing data
TABLE 1. Preoperative demographics and clinical
variables by HbA1c risk group
HbA1c < 7.0% HbA1c $ 7.0%
Risk factor N 5 2275 (%) N 5 814 (%) P value
Diabetes mellitus 516 (22.7%) 724 (88.9%) ,.001
Age (mean 6 SD) 63.0 6 10.9 61.6 6 10.0 ,.001
Female 581 (25.5%) 265 (32.6%) ,.001
Caucasian 1871 (84.2%) 596 (76.0%) ,.001
Renal failure 104 (4.6%) 75 (9.2%) ,.001
Stroke 198 (8.7%) 91 (11.2%) .037
NYHA class IV 446 (19.8%) 172 (21.4%) .341
CCS class 401 (17.9%) 131 (16.3%) .319
Hypertension 1783 (78.4%) 718 (88.2%) ,.001
Left main disease 505 (22.2%) 153 (18.8%) .042
No. diseased vessels
(mean 6 SD)
3.55 6 0.64 3.64 6 0.58 ,.001
Chronic lung disease 304 (13.4%) 93 (11.4%) .156
Arrhythmia 183 (8.0%) 49 (6.0%) .060
Peripheral vascular
disease
310 (13.6%) 143 (17.6%) .006
Perioperative factors
Intraoperative
glucose mg/dL
(mean 6 SD)
125.5 (19.7) 143.1 (29.0) ,.001
Postoperative
glucose mg/dL
(mean 6 SD)
125.7 (24.0) 154.2 (46.5) ,.001
Arterial grafts (mean
6 SD)
1.39 6 0.72 1.40 6 0.72 .606
Vein grafts (mean 6
SD)
1.88 6 1.07 1.95 6 1.06 .105
Total grafts (mean6
SD)
3.27 6 1.02 3.36 6 1.01 .040
CPB time (min, mean
6 SD)
99.1 6 27.9 101.2 6 27.2 .465
CPB used 661 (29.1%) 283 (34.7%) .002
LITA or BITA used 2165 (95.2%) 782 (96.1%) .291
HbA1c, Hemoglobin A1c; NYHA, New York Heart Association; CCS, Cana-
dian Cardiovascular Society; SD, standard deviation; CPB, cardiopulmonary
bypass; LITA, left internal thoracic artery; BITA, bilateral internal thoracic
artery. Intraoperative glucose5 postoperative day 0. Postoperative glucose
5 postoperative days 1–3.The Journal of Thofrom being excluded from the analysis, multiple imputationmethods
described by Rubin19 were used to impute missing values. The goal
of multiple imputations is not to replace data with plausible values
but rather to impute with values that will maintain the covariance
structure so that valuable data that are not missing will not be omit-
ted from analysis. Ten separate multiple imputations were generated
(using PROC MI, SAS version 9.1, SAS Institute Inc, Cary, NC),
and the results were combined (using PROC MIANALYZE) to
evaluate all model terms.
Separate multiple logistic regression models (one for each binary
outcome) were constructed using HbA1c as the primary variable of
interest and adjusting for the other 22 risk factors (Table 1). Of in-
terest was whether HbA1c, modeled as a continuous factor, was pre-
dictive of adverse outcomes in the presence of diabetes status and
other potential confounders. Adjusted odds ratios (ORs) were re-
ported and measure the additional increase in odds of outcome
per unit increase in HbA1c.
For each binary adverse event outcome, 2 models were con-
structed. The first type of model is an adjusted model (accounting
for all of the covariates) and is designed to measure the association
between HbA1c apart from the confounders. The second model is
unadjusted and designed to measure the ‘‘pure’’ effect of HbA1c
without any adjustors. To further evaluate the impact of HbA1c in
explaining each outcome, the discrimination of these models was
evaluated using the area under the receiver operating characteristic
(AUROC) curve, a measure of discrimination. AUROC is estimated
by the c-index, which was used for this study. Discrimination is the
model’s ability to distinguish between patients who have an event
and patients who do not have an event. The AUROC ranges from
0.50 to 1.00; values closer to 0.50 indicate poor discrimination,
and values closer to 1.00 indicate superior discrimination. Alterna-
tively, AUROCmay be thought of as the probability that a randomly
selected patient who has an adverse event will have a higher pre-
dicted probability of exhibiting the event than a randomly selected
unaffected patient. For each outcome and model, the AUROC was
computed for the logistic regression model.
Of further interest was to identify the HbA1c threshold value that
maximized the AUROC as a binary predictor of adverse outcomes.
To evaluate this, HbA1c was constructed as a binary variable with
a threshold that was continually shifted by increments of 0.1% units.
Each time the thresholdwas shifted, the impact of the binary variable
was reevaluated in both the unadjusted and adjusted logistic models.
The threshold value whose resultant binary predictor maximized the
AUROC was recorded for each adverse outcome in the unadjusted
and adjustedmodels. TheOR for the unadjusted and adjusted thresh-
olds that maximized the AUROC was also computed and recorded.
LOS was examined with respect to continuous HbA1c using an
adjusted general linear model (analysis of covariance approach).
Partial tests were performed to test for a non-zero slope for the
HbA1c term.
The data were managed and analyzed with SAS version 9.1. All
statistical tests were evaluated using a 2-tailed .05 level of signifi-
cance. Model terms and statistical comparisons were preplanned.
The authors had full access to the data and take responsibility for
its integrity. All authors have read and agree to the article as written.
Preoperative Definitions
Definitions for preoperative variables were according to the Society
of Thoracic Surgeons National Database and are as follows: diabetesracic and Cardiovascular Surgery c Volume 136, Number 3 633
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need for antidiabetic agents; renal failure indicates whether a patient
has a history of renal failure or a creatinine level greater than 2;
stroke indicates whether a patient has a history of a central neuro-
logic deficit lasting more than 72 hours; left main coronary disease
indicates narrowing of the diameter of the lumen by more than 50%
in the left main coronary artery; peripheral vascular disease indicates
whether a patient has a history of claudication with exercise or rest,
amputation for arterial insufficiency, vascular surgery or percutane-
ous vascular intervention, or abdominal aortic occlusion or aneu-
rysm; chronic lung disease is determined by forced expiratory
volume in 1 second, history of inhaled or oral bronchodilator ther-
apy, use of steroids aimed at treating lung disease, and PAO2 and
PACO2 levels; arrhythmia indicates a history of arrhythmia (atrial fi-
brillation/flutter, ventricular tachycardia/fibrillation, third-degree
heart block) that has been documented and treated; hypertension
is documented as history of hypertension treated with medication,
diet, or exercise, or systolic blood pressure greater than 140 or dia-
stolic blood pressure greater than 90 on 2 separate occasions, or cur-
rently receiving antihypertensive medication. Canadian
Cardiovascular Society classification was used to define angina
and the New York Heart Association criteria (The Criteria Commit-
tee) were used to define congestive heart failure.
Postoperative Definitions
Definitions for postoperative outcomes were also according to the
Society of Thoracic Surgeons National Database and are as follows:
in-hospital death indicates whether a patient died during the hospi-
talization in which CABG was performed; renal failure indicates
acute renal failure in which serum creatinine was elevated more
than 2.0 and 2 times the most recent preoperative creatinine level;
MI indicates a creatine kinase-MB elevation 5 or more times the up-
per limit of normal and presence of Q waves in 2 or more contiguous
ECG leads during the initial 24 postoperative hours, or evolutionary
ST-segment changes or new left bundle branch block or the afore-
mentioned criteria after the initial 24 postoperative hours; CVA in-
dicates whether a patient had a central neurologic deficit persisting
more than 72 hours (permanent stroke), transient ischemic attack,
deficit resolving within 24 hours, or deficit lasting more than 24
hours but less than 72 hours (reversible ischemic neurologic deficit);
DSWI indicates whether a patient had an infection involving mus-
cle, bone, or mediastinum requiring operative intervention; atrial fi-
brillation indicates whether a patient developed new-onset atrial
fibrillation in the postoperative setting. In addition to these compli-
cations, we included a composite of infection index that included the
presence of any sternal wound infection (deep or superficial), pneu-
monia, or septicemia.
Results
A total of 3089 of 3555 patients (86.9%) from April 4, 2002,
to June 30, 2006, were analyzed in this analysis (2275 with
HbA1c , 7%, 814 with HbA1c $ 7%). Beginning in
2002, as part of our routine preoperative labs, we obtained
preoperative HbA1c levels in all patients undergoing elective
CABG. The lack of uniform adoption of this screening
method until July of 2002 accounts for the fact that only
87% of patients had HbA1c levels obtained during the study634 The Journal of Thoracic and Cardiovascular Surgery c Sepperiod. Preoperative demographics, clinical variables, and
perioperative factors comparing patients with HbA1c greater
than or less than 7 are listed in Table 1. Forty-two percent
(516/1240) of diabetic patients were well-controlled with
HbA1c levels less than 7%. Of note, 4.9% (90/1849) of pa-
tients without a history of diabetes had HbA1c levels of
7% or greater, suggesting undiagnosed and/or untreated dia-
betes mellitus. Similarly, 11% (90/814) of patients with
HbA1c levels of 7% or greater had no history of diabetes.
Most patients in this study had multivessel coronary disease,
more than 95% of patients received arterial grafting with the
left internal thoracic artery or bilateral internal thoracic artery
grafting, and the majority of cases were performed without
the use of CPB. The mean glucose values for the day of sur-
gery (r5 0.37) and postoperative days 1 to 3 (r5 0.40) were
both moderately correlated with preoperative HbA1c values.
Unadjusted Outcomes
In-hospital outcomes are summarized by HbA1c subgroup in
Table 2. For all patients (N5 3089), the overall incidence of
major adverse events (death, CVA, or MI) was low (3.0%).
All outcomes were significantly worse in those patients
with HbA1c levels of 7% or more, with the exception of post-
operative MI and atrial fibrillation. The preoperative method
of glucose control for patients with a history of diabetes was
also significantly different between groups (P 5 .006). In
diabetic patients with HbA1c less than 7%, glucose was con-
trolled with diet alone in 20.5% (106), oral hypoglycemic
medications in 58.7% (303), and subcutaneous insulin in
18.8% (97). In diabetic patients with HbA1c of 7% or
more, glucose was controlled with diet alone in 10.5%
(76), oral hypoglycemic medications in 51.5% (373), and
subcutaneous insulin in 37.9% (275). Patients who were
managed with a combination of oral hypoglycemic
TABLE 2. In-hospital outcomes for all patients by HbA1c
risk group
HbA1c < 7.0% HbA1c $ 7.0%
Outcomes N 5 2275 (%) N 5 814 (%) P value
Death 18 (0.8%) 13 (1.6%) .048
Renal failure 40 (1.8%) 40 (4.9%) ,.001
MI 7 (0.3%) 4 (0.5%) .45
CVA 30 (1.3%) 23 (2.8%) .005
DSWI 10 (0.4%) 19 (2.3%) ,.001
Composite infection
scorea
21 (0.9%) 26 (3.2%) ,.001
Atrial fibrillation 427 (18.8%) 122 (15.0%) .015
LOS (d, mean 6 SD) 5.90 6 4.47 d 6.88 6 5.91 d ,.001
MI,Myocardial infarction; CVA, cerebrovascular accident; DSWI, deep ster-
nal wound infection; LOS, length of stay; SD, standard deviation. aInfection
is a composite index of any sternal wound infection (deep or superficial),
pneumonia, or septicemia.tember 2008
Halkos et al Surgery for Acquired Cardiovascular DiseaseTABLE 3. In-hospital outcomes for patients classified by HbA1c level and history of diabetes mellitus
Outcomes HbA1c < 7.0% HbA1c $ 7.0%
No DM Yes DM No DM Yes DM
Diabetes status N 5 1759 (%) N 5 516 (%) P value N 5 90 (%) N 5 724 (%) P value
Death 15 (0.9%) 3 (0.6%) .54 3 (3.3%) 10 (1.4%) .16
Renal failure 26 (1.5%) 14 (2.7%) .061 2 (2.2%) 38 (5.3%) .21
MI 6 (0.3%) 1 (0.2%) .60 0 (0) 4 (0.6%) .48
CVA 21 (1.2%) 9 (1.7%) .34 2 (2.2%) 21 (2.9%) .71
DSWI 7 (0.4%) 3 (0.6%) .58 0 (0) 19 (2.6%) .12
Composite infection
scorea
12 (0.7%) 9 (1.7%) .027 1 (1.1%) 25 (3.5%) .23
Atrial fibrillation 319 (18.1%) 108 (20.9%) .16 13 (14.4%) 109 (15.1%) .88
LOS (d, mean 6 SD) 5.7 6 3.9 6.5 6 6.0 .011 6.0 6 4.0 7.0 6 6.1 .043
DM,Diabetes mellitus;MI,myocardial infarction; CVA, cerebrovascular accident; DSWI, deep sternal wound infection; LOS, length of stay. aInfection is a com-
posite index of any sternal wound infection (deep or superficial), pneumonia, or septicemia.A
CDmedications and subcutaneous insulin therapy were grouped
into those who received subcutaneous insulin. Pre- and post-
operative treatment with aspirin, beta-blockers, and statins
were not significantly between HbA1c groups. Preopera-
tively, approximately 77% of patients received aspirin,
70% of patients received beta-blockers, and 21% of patients
received statins. Angiotensin-converting enzyme inhibitors
were used more often in patients with HbA1c of 7% or
more (38.6% vs 32.3%, P 5 .001). Postoperatively, approx-
imately 93% of patients received aspirin, 93% of patients re-
ceived beta-blockers, and 90% of patients received statins.
Angiotensin-converting enzyme inhibitors were used more
often in patients with HbA1c of 7% or more (43.8% vs
32.1%, P , .001). Of the 18 deaths in patients with HbA1c
less than 7%, 10 were cardiac related and 8 were due to var-
ious causes (intraoperative [1], multisystem organ failure [2],
pulmonary [3], renal failure [1], stroke [1]). Of the 13 deaths
in patients with HbA1c of 7% or more, 9 were cardiac related.
One patient died of complications of stroke, and 3 patients
TABLE 4. In-hospital outcomes among diabetic patients
according to HbA1c level
HbA1c < 7.0% HbA1c $ 7.0%
N 5 516 (%) N 5 724 (%) P value
Death 3 (0.6%) 10 (1.4%) .173
Renal failure 14 (2.7%) 38 (5.3%) .028
Myocardial infarction 1 (0.2%) 4 (0.6%) .326
CVA 9 (1.7%) 21 (2.9%) .191
DSWI 3 (0.6%) 19 (2.6%) .007
Infectiona 9 (1.7%) 25 (3.5%) .069
Atrial fibrillation 108 (20.9%) 109 (15.1%) .007
LOS (d, mean 6 SD) 6.5 6 6.0 7.0 6 6.1 .124
CVA, Cerebrovascular accident; DSWI, deep sternal wound infection; LOS,
length of stay; SD, standard deviation. aInfection is a composite index of any
sternal wound infection (deep or superficial), pneumonia, or septicemia.The Journal of Thodied of pulmonary complications. There were 34 of 1648 pa-
tients (2.1%) with HbA1c less than 7% and 9 of 540 patients
(1.7%) with HbA1c of 7% or greater who were converted
from off- to on-pump CABG. There were 4 deaths in the
group with HbA1c less than 7% and 0 deaths in the group
with HbA1c of 7% or more.
Table 3 lists adverse event outcomes by HbA1c risk group
subdivided into the presence or absence of history of diabetes
mellitus. In those patients with HbA1c less than 7%, there
were no statistical differences in morbidity by diabetes status
with the exception of a higher risk of the composite of infec-
tion in the diabetic patients (1.7% vs 0.7%, P5 .027). There
was, however, a significant increase in length of stay in dia-
betic patients in each HbA1c group.
Unadjusted outcomes for diabetic patients were also clas-
sified according to HbA1c risk status to evaluate outcomes
among diabetic patients with well-controlled diabetes
(HbA1c , 7%) versus those with suboptimal control
(HbA1c $ 7%) (Table 4). The incidence of adverse events
was significantly higher for the patients with uncontrolled di-
abetes (HbA1c $ 7% group), including renal failure (P 5
.028), DSWI (P 5 .007), and the composite index of infec-
tion (0.069). Although there was a trend toward more mortal-
ity in patients with uncontrolled diabetes (1.4%) compared
with those with controlled diabetes (0.6%), this did not reach
statistical significance.
Patients were further classified according to their diabetes
status without respect to their HbA1c status. Diabetic patients
had significantly higher incidences of renal failure, stroke,
DSWI, the composite index of infection, and longer LOS
(Table 5). There were no significant differences in in-hospital
mortality based on diabetes status.
Adjusted Outcomes
The primary aim of this cohort study was to determine
whether HbA1c was an independent risk factor for adverseracic and Cardiovascular Surgery c Volume 136, Number 3 635
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risk groups in Tables 2 to 5 for descriptive purposes, it was
modeled as a continuous factor in multivariable logistic re-
gression models (Table 6). Higher HbA1c percentage, ad-
justed for the 22 covariates, was associated with increased
incidence of death (OR 5 1.40, P 5 .019), MI (OR 5
1.55, P 5 .05), and DSWI (1.38, P 5 .029) for each unit in-
crease in HbA1c. Higher HbA1c was protective of develop-
ing atrial fibrillation (0.89, P 5 .014).
The thresholds that maximize the AUROC when using
HbA1c as a binary variable in unadjusted and adjusted
models are listed in Table 7. Patients with HbA1c values of
8.6% or more have adjusted odds of death 4.41 times higher
than patients with values below that threshold. Similar
thresholds exist for renal failure (6.7%, OR 5 2.10), CVA
(7.6%, OR 5 2.23), and DSWI (7.8%, OR 5 5.29). Higher
HbA1c is protective of atrial fibrillation (6.8%, OR 5
0.73). The model to identify a threshold value for periopera-
tive MI was inestimable (because of small response, n5 11),
so no threshold value could be reliably determined.
TABLE 5. Outcomes according to diabetes status only,
irrespective of HbA1c level
No DM Yes DM
Diabetes status N 5 1849 (%) N 5 1240 (%) P value
Death 18 (0.97%) 13 (1.05%) .838
Renal failure 28 (1.5%) 52 (4.2%) ,.001
Myocardial infarction 6 (0.3%) 5 (0.4%) .719
CVA 23 (1.2%) 30 (2.4%) .014
DSWI 7 (0.4%) 22 (1.8%) ,.001
Infectiona 13 (0.7%) 34 (2.7%) ,.001
Atrial fibrillation 332 (18.0%) 217 (17.5%) .745
LOS (d, mean 6 SD) 5.8 (3.9%) 6.8 (6.1%) ,.001
DM, Diabetes mellitus; CVA, cerebrovascular accident; DSWI, deep sternal
wound infection; LOS, length of stay; SD, standard deviation. aInfection is
a composite index of any sternal wound infection (deep or superficial),
pneumonia, or septicemia.636 The Journal of Thoracic and Cardiovascular Surgery c SepThe unadjusted threshold was lower for death (7.7%,
OR 5 6.02). The unadjusted threshold for MI, which had
an inestimable adjusted threshold, was determined to be
9.8%, perhaps the weakest estimate because of the small
MI event rate.
Discussion
In the present study, we examined 3089 patients undergoing
elective primary CABG. Overall in-hospital mortality in all
patients was low (1.0%). However, HbA1c levels of 7% or
more in all patients was associated with a significant increase
in in-hospital mortality, renal failure, CVA, DSWI, and the
composite index of infection compared with patients with
HbA1c levels less than 7%. After adjustment, using a multi-
variate analysis with HbA1c as a continuous variable, the risk
of in-hospital death was significantly higher (P, .001) with
an OR of 1.40. This translates into a 40% increase in odds of
death for each unit increase in HbA1c. By using a receiver
operating characteristic curve analysis, which maximizes
the area under the curve and identifies the HbA1c threshold
TABLE 6. HbA1c adjusted odds ratios for adverse
outcomes, measuring the additional risk for every unit
increase in HbA1c percentage
Continuous HbA1c adjusted
Adverse outcome OR (95% CI) P value
Death 1.40 (1.06–1.86) .019
Renal failure 1.12 (0.94–1.33) .21
Myocardial infarction 1.55 (1.00–2.41) .05
CVA 1.07 (0.86–1.34) .54
DSWI 1.38 (1.03–1.84) .029
Infectiona 1.18 (0.96–1.45) .13
Atrial fibrillation 0.89 (0.80–0.98) .014
Blood products 0.99 (0.92–1.06) .72
OR, Odds ratio; CVA, cerebrovascular accident; DSWI, deep sternal wound
infection. aInfection is a composite of any stern wound infection (deep or
superficial), pneumonia, or septicemia.TABLE 7. Threshold values that maximize the area under the receiver operating characteristic curve in adjusted and
unadjusted models
Adjusted ROC estimates Unadjusted ROC estimates
Adverse outcome Threshold value AUROC OR Threshold value AUROC OR
Death 8.6 0.906 4.41 (1.44–13.42) 7.7 0.590 6.02 (2.16–16.80)
Renal failure 6.7 0.792 2.10 (1.16–3.30) 6.7 0.633 3.03 (1.94–4.76)
MI Inestimable model – – 9.8 0.607 6.07 (1.60–23.09)
CVA 7.6 0.791 2.23 (1.06–4.70) 7.2 0.590 2.31 (1.33–4.02)
DSWI 7.8 0.801 5.29 (2.00–14.00) 7.7 0.725 7.90 (3.71–16.83)
Infectiona 7.5 0.761 1.98 (0.96–4.09) 6.9 0.650 3.58 (2.00–6.42)
Atrial fibrillation 6.8 0.687 0.73 (0.55–0.96) 7.1 0.530 0.72 (0.57–0.90)
MI,Myocardial infarction; CVA, cerebrovascular accident; DSWI, deep sternal wound infection; ROC, receiver operating characteristic; AUROC, area under
the receiver operating characteristic. aInfection is a composite of any stern wound infection (deep or superficial), pneumonia, or septicemia.tember 2008
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(unadjusted) threshold value for HbA1c was 8.6 (7.7) for
in-hospital death with an adjusted OR of 4.4 and an unad-
justed OR of 6.0. This translates to a 4-fold increase in the
risk of in-hospital death for patients with HbA1c more than
8.6%.
In this study, 1240 of 3089 patients (40%) presented with
a history of diabetes mellitus. Even within the Emory Health-
care System, we have seen an increase in diabetic patients re-
ferred for surgical revascularization. In our previous report,2
only 19% of patients undergoing CABG from 1978 to 1993
had a history of diabetes mellitus. According to the Bypass
Angioplasty Revascularization Investigation, patients with
multivessel disease had improved survival when treated
with an initial strategy of CABG versus percutaneous inter-
vention.20 Therefore, we expect a larger proportion of pa-
tients with multivessel coronary disease to be referred for
surgical revascularization.
Recent studies comparing diabetic and nondiabetic pa-
tients after CABG have yielded conflicting results regarding
in-hospital and short-term outcomes. Calafiore and col-
leagues6 showed that diabetes was an independent risk factor
for early cardiac death only and not for all-cause mortality.
Rajakaruna and associates5 found in a risk-adjusted analysis
that diabetic patients had mortality outcomes comparable to
those of nondiabetic patients. Kubal and coworkers7 showed
that insulin-dependent diabetic patients had an increased risk
of postoperative morbidity, but that just the history of diabe-
tes was not associated with increased mortality. Other studies
have refuted these claims, including work by Carson and col-
leagues,3 Thourani and colleagues,2 and Woods and col-
leagues.4 In several of these studies, the mode of glycemic
control was used to stratify diabetic patients into those with
glucose controlled with oral hypoglycemic medications ver-
sus insulin therapy,2,7 as well as those with other complica-
tions of diabetes, such as renal failure and peripheral
vascular disease.21 The largest study to date by Carson and
colleagues3 examined outcomes in 41,663 diabetic patients
compared with 105,123 nondiabetic patients and found that
patients with diabetes had a 23% to 37% increase in 30-day
mortality and in-hospital morbidity compared with patients
without diabetes. Some of these differences may be explained
by how diabetic patients were defined. For example, exclu-
sion of those with diet-controlled diabetes or exclusion of
those without a preoperative history of diabetes (which
may have occurred in retrospective analyses) may alter the
comparisons between groups.
The practice changes in the past decade compared with
earlier reported studies may also have affected the lack of
a mortality difference between diabetic and nondiabetic pa-
tients. Specifically, the routine use of the left internal thoracic
artery,22 improvements in anesthesia and critical care, the
use of off-pump CABG techniques, perioperative insulin in-
fusion,10–15 and improved secondary prevention protocols,23The Journal of Thoincluding antiplatelet medication, lipid-lowering regimens,
and preoperative glucose modulation with insulin and oral
hypoglycemic regimens, may have collectively improved
outcomes in diabetic patients undergoing CABG. These dif-
ferences may make interpretation of older studies24–28 less
reliable compared with current reports. In the present study,
we sought to determine whether these outcome differences
could be explained by preoperative glycemic control (as
measured by HbA1c) rather than the mere history of diabetes
mellitus.
One of the most dramatic improvements in outcomes
among diabetic patients has been the implementation of tight
perioperative glucose control. Furnary and colleagues10,14,15
reported dramatic reductions in mortality and DSWI among
diabetic patients (comparable to nondiabetic patients) man-
aged with a continuous insulin infusion initiated intraopera-
tively and maintained through the first 2 postoperative
days. The authors attributed these improvements to enhanced
myocardial glycometabolic function associated with eugly-
cemia achieved by continuous insulin infusion. We aimed
to regulate glucose levels between 80 and 110 mg/dL in all
patients in the operating room and in the intensive care unit
using a continuous insulin infusion. Once patients were trans-
ferred to the telemetry unit, management was variable and de-
pendent on their control in the intensive care unit. This
included the use of continuous insulin infusion, scheduled
subcutaneous insulin therapy, and a sliding scale. Although
patients with preoperative HbA1c 7% or more had signifi-
cantly higher intra- and postoperative mean glucose levels
compared with patients with HbA1c less than 7%, the
mean glucose levels in patients with HbA1c 7% or more
(day 0: 143 mg/dL, days 1–3: 154 mg/dL) were comparable
to those of diabetic patients in other studies.10–15 Although
we did not achieve the desired target blood glucose levels
in the operating room and intensive care unit, perioperative
glucose control was reasonable. In addition, preoperative
HbA1c level still emerged as an independent predictor of
mortality and DSWI after CABG in the multivariate analysis,
even after adjusting for mean glucose levels on the day of sur-
gery and the first 3 postoperative days. This is in contrast with
the findings of Furnary and Wu,10 which did not identify
HbA1c as a risk factor. Therefore, we agree with previous au-
thors that strict intraoperative and postoperative glucose con-
trol is imperative to minimize both postoperative morbidity
and mortality after CABG. However, it is plausible from
these data that HbA1c is also an independent predictor of
postoperative adverse events that is not entirely due to intra-
and postoperative glucose control. This is most likely ex-
plained by the associated comorbidities that patients with
long-standing diabetes present with before CABG, including
renal insufficiency, cerebrovascular disease, hypertension,
and more advanced coronary artery disease as seen in the pre-
operative comorbidities in our patients with elevated HbA1c.
In addition to predicting adverse events, it may be moreracic and Cardiovascular Surgery c Volume 136, Number 3 637
Surgery for Acquired Cardiovascular Disease Halkos et al
A
CDdifficult to achieve intra- and postoperative euglycemia in pa-
tients with elevated HbA1c. Therefore, more aggressive glu-
cose management should be used in these patients in the
perioperative period.
HbA1c reflects a patient’s glucose control during the pre-
ceding 3 to 4 months. Current practice guidelines according
to the American Diabetes Association recommend routine
HbA1c screening of diabetic patients as frequently as every
3months in patients with elevated A1c levels ($7%) or in pa-
tients with medication adjustments to ensure an adequate
treatment regimen.13 Current recommendations suggest that
patients with diabetes aim to achieve HbA1c levels of at least
less than 7%.17,18,29,30 We chose to order HbA1c for all pa-
tients starting in 2002 (even those without a history of diabe-
tes) to determine whether this approach would identify
patients who had uncontrolled hyperglycemia without a pre-
vious diagnosis of diabetes mellitus. As seen in Table 3, 90
patients in this study without a previous diagnosis of diabetes
had preoperative HbA1c levels of 7% or greater. This promp-
ted confirmatory diagnosis in the postoperative setting and
endocrinology consultation for management of diabetes.
To our knowledge, this is one of the few studies that as-
sessed whether HbA1c, the standard measure to assess
long-term glucose control, is a potential risk factor for ad-
verse outcomes in patients undergoing CABG.10 It is possi-
ble that a preoperative HbA1c level may provide more
accurate prognostic information about outcomes after
CABG compared with a diabetes status alone. In patients
with diabetes but with good long-term preoperative glycemic
control (HbA1c , 7%), outcomes (with the exception of the
composite index of infection) were comparable to those of
patients without a diagnosis of diabetes and with HbA1c
less than 7%. In addition, we implemented continuous insulin
infusion to achieve glucose control on the day of surgery and
in the intensive care unit. This may have accounted for the
lack of a mortality difference between diabetic patients and
nondiabetic patients in the unadjusted analysis. Because
other studies evaluating the impact of diabetes on morbidity
and mortality after CABG have resulted in different conclu-
sions, we hypothesize that some of these differences may in
part be due to the lack of a standardized measure (HbA1c) to
adjust for significant differences in long-term preoperative
glycemic control. This would apply to all diabetic patients,
irrespective of the mode of therapy used for glucose control,
suggesting that some patients should begin more intense glu-
cose control with insulin therapy before CABG.Moreover, in
patients with HbA1c greater than 8.7% and not requiring an
urgent or emergency CABG, consideration should be given
to maximizing blood glucose control before surgery to min-
imize morbidity and mortality.
Limitations
Our study has the inherent biases of any retrospective review
of a prospectively collected database. Although we con-638 The Journal of Thoracic and Cardiovascular Surgery c Setrolled for multiple variables, there may still be confounding
factors that may have altered the results. For instance, even
though we controlled for perioperative glucose values in
the multivariable analysis, it is possible that better glucose
control in patients with an elevated HbA1cmay have reduced
adverse events in this group. Furthermore, although we en-
deavored to only use a limited set of confounders, for some
outcomes with rare event rates (MI), the number of covariates
might be disproportionately higher than the ‘‘rule of 10’’ (at
least 10 events for every covariate added to a model) would
suggest. Our study population may be different from those of
other studies with regard to surgical approach and periopera-
tive care. Approximately 70% of patients underwent CABG
without the use of CPB. All patients were treated with a strict
perioperative insulin infusion and then transitioned to subcu-
taneous insulin to target blood glucose less than 150 mg/dL.
Although we used a multivariate analysis model, we did not
use propensity matching in our subgroup analyses. The goal
of propensity scoring is to identify whether some intervention
is associated with an outcome while working to balance these
intervention groups with respect to their other preoperative
characteristics. The problem with propensity scoring in our
present study is that there is no intervention; HbA1c is
a pure preoperative risk factor and not any type of interven-
tion. Furthermore, we did not determine whether insulin-de-
pendent patients had worse outcomes compared with those
with diabetes controlled with diet or oral hypoglycemic med-
ications, as has been done in other studies. In this study, only
patients who reported a history of diabetes preoperatively
were classified as ‘‘diabetic.’’ In this retrospective analysis,
patients with no known history of diabetes were classified
as ‘‘nondiabetic’’ even if they were determined to be diabetic
in the postoperative period. In these patients, their diagnosis
would have been overlooked without a preoperative HbA1c
level.
Conclusions
This study showed that HbA1c is a powerful predictor of in-
hospital death and morbidity. HbA1c may be a more accurate
predictor of outcomes than merely a diagnosis of diabetes,
with the added benefit of quantification of diabetes as a risk
factor. This simple laboratory test drawn preoperatively
may provide the clinician with a more accurate risk profile
and provide additional prognostic information when discus-
sing morbidity and mortality risks with patients and their
families. Whether this warrants practice changes in patients
with poorly controlled or newly diagnosed diabetes will be
the subject of future investigation.
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Discussion
Dr Harold L. Lazar (Boston, Mass). In their study, Dr Halkos and
colleagues found that an elevated preoperative HbA1c level was as-
sociated with a significant increase in mortality and morbidity. This
is not surprising because patients with an elevated HbA1c had
a higher incidence of preoperative renal failure, strokes, peripheral
vascular disease, and diffuse coronary artery disease, which required
more grafts. All of these factors are independently known to be pre-
dictive of adverse outcomes after bypass surgery.
My first question is whether an elevated HbA1c is a marker of
advanced diabetic end-organ disease or does it really represent
poor intraoperative glycemic control? Did you actually measure
the perioperative glucose values between the high and low HbA1c
groups to see whether or not your protocols actually achieved tight
glycemic control in the elevated HbA1c group, and did the patients
with elevated HbA1c levels who had lower perioperative glucose
values have decreased morbidity and mortality?
DrHalkos.Letmefirst start by addressing the question regarding
tight intraoperative glycemic control. We did not collect those data
because they were not accessible to us regarding the blood glucose
levels in the operating room and intensive care unit setting. However,
all of our patients undergoing primary electiveCABGaremaintained
in the same fashion with regard to the regimen in which their blood
glucose is controlled both in the operating room and in the intensive
care unit, as well as how they are transitioned on the floor.
Dr Lazar. I think that may be important data because we have
found that it is more difficult to achieve tighter glycemic control
in patients with elevated HbA1c even though there is a set protocol.
I may actually answer your first clinical implication as to whether or
not these patients can be delayed. Perhaps these patients may have to
have more vigorous intraoperative control of their glucose levels.
My second question is, were the adverse effects of an elevated
HbA1c related to the type of diabetes? In other words, did insulin-
dependent diabetic patients have worse outcomes compared with
patients treated with oral agents or diet alone?racic and Cardiovascular Surgery c Volume 136, Number 3 639
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tion that you asked regarding patients with elevated HbA1c: Are the
intraoperative and perioperative glucose levels or the comorbidities
associated with poorly controlled diabetes? We believe that it may
very well be the comorbidities associated with poorly controlled di-
abetes, which is reflected by an elevated HbA1c. With regard to the
last question, rephrase that last part for me.
Dr Lazar. Did insulin diabetic patients have worse outcomes
than those with oral agents or diet alone?
Dr Halkos. We did not look into the subgroupings of how dia-
betes was controlled in patients with regard to their method of con-
trol. In our study, approximately 20% of patients were receiving
insulin therapy, and then 50% were receiving oral hypoglycemic
medications or a combination thereof. So part of the reason for
not looking at the data in that fashion was the combination thereof
was not well defined in our database.
Dr Lazar. Patients in the elevated HbA1c group had signifi-
cantly higher mortality. What were the differences in the cause of
death between the groups? Were the patients with elevated HbA1c
more likely to die of cardiac causes or was it more related to their
increased incidence of renal fairly, strokes, and peripheral vascular
disease?
Dr Halkos. With regard to the cause of death, we really didn’t
look into the cause with regard to their cause of mortality other
than report the associated morbidities.
Dr Lazar. In your study, 70% of patients underwent off-pump
surgery, yet patients with an elevated HbA1c were more likely to un-
dergo on-pump surgery. What was the crossover rate from the off-
pump to the on-pump groups in this study, and were the patients
with an elevated HbA1c who crossed over more likely to have an640 The Journal of Thoracic and Cardiovascular Surgery c Sepadverse outcome? I must say these data were derived from the arti-
cle, which you were kind enough to send to me in advance.
Dr Halkos. Yes, sir. I don’t know the exact crossover rate, but I
know that during the period of the study it was very low, with a 2%
crossover. Patients were categorized according to whether they un-
derwent on- or off-pump surgery according to the ultimate proce-
dure that was used. So that is a piece of data that can be
misleading. We believe that even though slightly more patients un-
derwent on-pump surgery in the higher A1c subgroup, that was only
approximately 4% to 5% higher than the A1c group (,7%).
Dr Lazar. Recent studies have shown that patients receiving an-
giotensin-converting enzyme inhibitors, beta-blockers, and statins
in the perioperative period have decreased morbidity and mortality.
Can you tell us what percentage of patients in the study received
these medications and was there a difference in the use of these med-
ications between the HbA1c groups?
Dr Halkos. Again, almost all of our patients are managed in the
same way: They receive aspirin preoperatively, angiotensin-con-
verting enzyme inhibitors are discontinued preoperatively in almost
all patients, and they receive beta-blocker therapy.
Dr Lazar. One final question, again from the article. Your data
implied that elevated HbA1c levels were actually protective from
developing atrial fibrillation. In other words, people with elevated
HbA1c actually had a lower incidence of atrial fibrillation. Can
you explain that and give us an idea of what the mechanism was?
Dr Halkos.We reported all of these outcomes, and in this study,
which was not presented in the slides, there was a 30% lower inci-
dence of atrial fibrillation in patients with an elevated A1c, but this
was statistically significant, and we do not have a mechanism to
explain why that difference existed.tember 2008
